search
Back to results

SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS (SOPHIE)

Primary Purpose

Advanced Ovarian Cancer

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Multimodal Prehabilitation
Sponsored by
Hospital Clinic of Barcelona
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Advanced Ovarian Cancer focused on measuring Prehabilitation, Advanced ovarian cancer, cytoreductive surgery, postoperative complications, exercise training, nutrition, physical activity, mindfulness meditation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients with advanced ovarian cancer subject to primary debulking surgery or interval surgery after 3-4 cycles of chemotherapy or secondary and / or tertiary debulking surgery .
  2. Patients with Eastern Cooperative Oncology Group (ECOG) performance status 2-0.
  3. Adherence of at least 75 % of the program or minimum of 6 sessions.

Exclusion Criteria:

  1. Surgery without a minimum of 3 weeks of prehabilitation time.
  2. Unstable respiratory or heart disease.
  3. Locomotor or cognitive limitations that makes not feasible the adherence to the program.
  4. Refusal of the patient.

Sites / Locations

  • Hospital Clinic BarcelonaRecruiting
  • Biomedical Research Institute la Fe

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Usual care

Multimodal prehabilitation

Arm Description

Control group will follow the standard preoperative measures "Enhanced Recovery After Surgery" (ERAS®) established in the protocols of our hospital. Standard preoperative measures: recommendation of nutritional and physical activity and advice to stop smoking and reduce alcohol intake; optimization of preoperative pathologies including anaemia. An information document on ERAS® measures in our center will be attached to all of them.

Patients following the standard preoperative policies of our institution and the multimodal prehabilitation program

Outcomes

Primary Outcome Measures

Incidence of postoperative complications
Any deviation from the normal postoperative course and according its severity to the Clavien-Dindo classification, will be considered a complication. A comprehensive complication index (CCI) scale will be used which assigns a value to each Clavein-Dindo level so a weighted average of the severity of complications can be calculated not only in a qualitatively way, but also numerically.

Secondary Outcome Measures

Hospital and ICU (intensive care unit) length of stay
Compliance to the ERAS program.
Percentage of items of ERAS program that were completed. Key aspects of this protocol include prevention of prolonged fasting allowing oral intake of clear fluids up to 2 hours before induction of anaesthesia, carbohydrate loading, avoidance of mechanical bowel preparation except if a bowel resection is scheduled, thromboprophylaxis; pre-, intra-, and post-operative euvolemia via goal directed fluid therapy, maintenance of normothermia, intraoperative and postoperative opioid-sparing multi-modal analgesia, avoidance the use of surgical drains, early removal of the urine catheter, and an emphasis on early ambulation and feeding.
Interval of days between surgery and the start of chemotherapy
Preoperative and postoperative aerobic capacity
Maximum production of carbon dioxide in ml/min during high intensity cardiopulmonar exercise.
Cost-effectiveness
Cost of treatment in the hospital in Euros including prehabilitation and postoperative recovery.
Health Related Quality of Life assesed by EORTC QLC-C30
Incidence of cognitive deficit
Cognitive assessment based on validated neuropsychological test: T @ M (; Digits WAIS III (Wechsler Adult Intelligence Scale-Third Edition)
Overall and disease-free survival of the study groups
Nutritional status
GLIM (includes hand-grip)

Full Information

First Posted
April 12, 2021
Last Updated
March 4, 2023
Sponsor
Hospital Clinic of Barcelona
search

1. Study Identification

Unique Protocol Identification Number
NCT04862325
Brief Title
SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS
Acronym
SOPHIE
Official Title
SOPHIE: Surgery in Ovarian Cancer With PreHabilitation In ERAS: Prospective Multicentre Study
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2021 (Actual)
Primary Completion Date
December 1, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital Clinic of Barcelona

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The treatment of choice in advanced ovarian cancer is a cytoreductive surgery combined with chemotherapeutic treatment. This complex and aggressive surgery is associated with high postoperative complication rates that may result in a strong negative impact on the clinical results due to the delay with the start of adjuvant chemotherapy as well as the costs from the surgical process. Multimodal prehabilitation has emerged as an innovative intervention that focuses on optimizing physiological and psychological resilience to withstand the upcoming stress of surgery. It has been shown to reduce postoperative complications in major abdominal surgery, but has not been assessed yet in abdominal onco-gynecological surgery.
Detailed Description
Main objective: To determine the efficacy of multimodal prehabilitation in decreasing postoperative complications in patients undergoing gynecological cancer surgery of high complexity by laparotomy (primary cytoreductive surgery, interval surgery and secondary cytoreductive surgery in advanced ovarian cancer). Design: Multicenter randomized controlled clinical trial. Subjects: 146 patients: 73 in the intervention group and 73 in the control group. Intervention group: PreHAB intervention consists on: High-intensity endurance exercise training program and physical activity promotion remotely controlled with ICT (information and communications technologies). Nutritional counselling to achieve protein intake of 1.5-1.8 g/kg and whey protein supplements. Psychological coping. Control group will receive standard preoperative care. Both groups will receive perioperative care in accordance with the enhanced recovery after surgery (ERAS) guidelines. Measures: Aerobic capacity (incremental stress test), physical activity, operative complications and hospital length and associated costs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Ovarian Cancer
Keywords
Prehabilitation, Advanced ovarian cancer, cytoreductive surgery, postoperative complications, exercise training, nutrition, physical activity, mindfulness meditation

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
146 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Usual care
Arm Type
No Intervention
Arm Description
Control group will follow the standard preoperative measures "Enhanced Recovery After Surgery" (ERAS®) established in the protocols of our hospital. Standard preoperative measures: recommendation of nutritional and physical activity and advice to stop smoking and reduce alcohol intake; optimization of preoperative pathologies including anaemia. An information document on ERAS® measures in our center will be attached to all of them.
Arm Title
Multimodal prehabilitation
Arm Type
Experimental
Arm Description
Patients following the standard preoperative policies of our institution and the multimodal prehabilitation program
Intervention Type
Other
Intervention Name(s)
Multimodal Prehabilitation
Intervention Description
High-intensity endurance exercise training program and physical activity promotion remotely controlled with ICT (information and communications technologies). Nutritional counselling to achieve protein intake of 1.5-1.8 g/kg and whey protein supplements. Psychological intervention including motivational interview, mindfulness meditation and cognitive behavioral therapy
Primary Outcome Measure Information:
Title
Incidence of postoperative complications
Description
Any deviation from the normal postoperative course and according its severity to the Clavien-Dindo classification, will be considered a complication. A comprehensive complication index (CCI) scale will be used which assigns a value to each Clavein-Dindo level so a weighted average of the severity of complications can be calculated not only in a qualitatively way, but also numerically.
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Hospital and ICU (intensive care unit) length of stay
Time Frame
postoperative 30 days
Title
Compliance to the ERAS program.
Description
Percentage of items of ERAS program that were completed. Key aspects of this protocol include prevention of prolonged fasting allowing oral intake of clear fluids up to 2 hours before induction of anaesthesia, carbohydrate loading, avoidance of mechanical bowel preparation except if a bowel resection is scheduled, thromboprophylaxis; pre-, intra-, and post-operative euvolemia via goal directed fluid therapy, maintenance of normothermia, intraoperative and postoperative opioid-sparing multi-modal analgesia, avoidance the use of surgical drains, early removal of the urine catheter, and an emphasis on early ambulation and feeding.
Time Frame
postoperative 30 days
Title
Interval of days between surgery and the start of chemotherapy
Time Frame
From date of surgery up to 6 months
Title
Preoperative and postoperative aerobic capacity
Description
Maximum production of carbon dioxide in ml/min during high intensity cardiopulmonar exercise.
Time Frame
baseline, 1 and 3 month post intervention
Title
Cost-effectiveness
Description
Cost of treatment in the hospital in Euros including prehabilitation and postoperative recovery.
Time Frame
Baseline up to 30 days after surgery
Title
Health Related Quality of Life assesed by EORTC QLC-C30
Time Frame
Baseline and 1 month postoperative
Title
Incidence of cognitive deficit
Description
Cognitive assessment based on validated neuropsychological test: T @ M (; Digits WAIS III (Wechsler Adult Intelligence Scale-Third Edition)
Time Frame
Baseline and 1 month postoperative
Title
Overall and disease-free survival of the study groups
Time Frame
5 years
Title
Nutritional status
Description
GLIM (includes hand-grip)
Time Frame
Baseline and 1 month postoperative

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with advanced ovarian cancer subject to primary debulking surgery or interval surgery after 3-4 cycles of chemotherapy or secondary and / or tertiary debulking surgery . Patients with Eastern Cooperative Oncology Group (ECOG) performance status 2-0. Adherence of at least 75 % of the program or minimum of 6 sessions. Exclusion Criteria: Surgery without a minimum of 3 weeks of prehabilitation time. Unstable respiratory or heart disease. Locomotor or cognitive limitations that makes not feasible the adherence to the program. Refusal of the patient.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Berta Diaz-Feijoo, MD PHD
Phone
932275400
Ext
5534
Email
bdiazfe@clinic.cat
First Name & Middle Initial & Last Name or Official Title & Degree
M Jose Arguis, MD PHD
Phone
932275400
Ext
5534
Email
mjarguis@clinic.cat
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Berta Diaz-Feijoo, MD PHD
Organizational Affiliation
Hospital Clinic of Barcelona
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
M Jose Arguis, MD
Organizational Affiliation
Hospital Clinic of Barcelona
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Clinic Barcelona
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Berta Diaz-Feijoo, MD PHD
Phone
932275400
Ext
5534
Email
bdiazfe@clinic.cat
Facility Name
Biomedical Research Institute la Fe
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Individual Site Status
Active, not recruiting

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28489682
Citation
Barberan-Garcia A, Ubre M, Roca J, Lacy AM, Burgos F, Risco R, Momblan D, Balust J, Blanco I, Martinez-Palli G. Personalised Prehabilitation in High-risk Patients Undergoing Elective Major Abdominal Surgery: A Randomized Blinded Controlled Trial. Ann Surg. 2018 Jan;267(1):50-56. doi: 10.1097/SLA.0000000000002293.
Results Reference
background
PubMed Identifier
35793862
Citation
Diaz-Feijoo B, Agusti N, Sebio R, Siso M, Carreras-Dieguez N, Domingo S, Diaz-Cambronero O, Torne A, Martinez-Palli G, Arguis MJ. A multimodal prehabilitation program for the reduction of post-operative complications after surgery in advanced ovarian cancer under an ERAS pathway: a randomized multicenter trial (SOPHIE). Int J Gynecol Cancer. 2022 Jul 6:ijgc-2022-003652. doi: 10.1136/ijgc-2022-003652. Online ahead of print.
Results Reference
derived

Learn more about this trial

SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS

We'll reach out to this number within 24 hrs